IQVIA (NYSE:IQV) Upgraded to Buy at StockNews.com

StockNews.com upgraded shares of IQVIA (NYSE:IQV) from a hold rating to a buy rating in a research report released on Wednesday.

A number of other research analysts have also commented on IQV. Morgan Stanley upped their price objective on shares of IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, July 23rd. Barclays dropped their price target on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research report on Tuesday, October 15th. Royal Bank of Canada began coverage on shares of IQVIA in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price target for the company. Truist Financial cut their target price on shares of IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a research note on Monday, October 14th. Finally, Redburn Atlantic began coverage on shares of IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 target price for the company. Four investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $261.24.

IQVIA Stock Up 1.6 %

Shares of IQV opened at $209.16 on Wednesday. The company has a 50-day simple moving average of $234.31 and a 200-day simple moving average of $229.74. The firm has a market capitalization of $38.13 billion, a P/E ratio of 27.16, a P/E/G ratio of 2.11 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. IQVIA has a 52 week low of $181.03 and a 52 week high of $261.73.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

Institutional investors and hedge funds have recently made changes to their positions in the company. Jennison Associates LLC lifted its position in IQVIA by 7.3% in the 1st quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock valued at $35,636,000 after acquiring an additional 9,578 shares in the last quarter. PGGM Investments increased its stake in shares of IQVIA by 55.8% during the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after purchasing an additional 4,326 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of IQVIA by 80.1% during the 1st quarter. SG Americas Securities LLC now owns 45,787 shares of the medical research company’s stock worth $11,579,000 after purchasing an additional 20,369 shares during the last quarter. Quadrature Capital Ltd acquired a new position in IQVIA in the 1st quarter valued at about $3,365,000. Finally, BNP Paribas acquired a new position in IQVIA in the 1st quarter valued at about $1,096,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.